Last reviewed · How we verify
DRL_RI
At a glance
| Generic name | DRL_RI |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (PHASE3)
- A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (PHASE3)
- Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DRL_RI CI brief — competitive landscape report
- DRL_RI updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI